Epigenetic Abnormalities in Cancer Find a “Home on the Range”  by Easwaran, Hariharan & Baylin, Stephen B.
Cancer Cell
PreviewsEpigenetic Abnormalities in Cancer Find
a ‘‘Home on the Range’’Hariharan Easwaran1,* and Stephen B. Baylin1,*
1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
*Correspondence: heaswar2@jhmi.edu (H.E.), sbaylin@jhmi.edu (S.B.B.)
http://dx.doi.org/10.1016/j.ccr.2012.12.018
Recent studies have highlighted large genomic regions prone to undergo epigenetic changes in cancers. In
this issue of Cancer Cell, Bert and colleagues describe novel genomic domains with aberrant epigenetic
changes involving concordant activation of neighboring genes. These domains involve aberrant CpG-island
hypermethylation similar to that observed in gene silencing.One of the most exciting areas of biology
in the last decade is the explosion of
knowledge about the organization and
regulatory features of human normal
(Dunham et al., 2012) and cancer (Baylin
and Jones, 2011) epigenomes. Increas-
ingly, it has become evident that epige-
netic changes in cancer constitute driver
events in tumorigenesis, and exome
sequencing studies have revealed recur-
rent mutations in key chromatin modifiers
in multiple tumor types (You and Jones,
2012). Most studies concerning epige-
netic deregulation in cancer have con-
centrated on abnormal transcriptional
silencing (Baylin and Jones, 2011). In
this issue of Cancer Cell, Bert et al.
(2013) describe a phenomenon of epige-
netic deregulation involving exactly the
opposite: abnormal upregulation of gene
expression that occurs in clusters of
genes, hence termed ‘‘long-range epige-
netic activation’’ (LREA) domains (Fig-
ure 1A). These findings extend a growing
theme in cancer epigenetics: abnormal
epigenetic deregulation of adjacent genes
within large chromosomal regions, a
concept with important ramifications for
how chromatin boundaries exist normally
and abnormally and how they go awry
in cancer. We consider the current paper
in the context of topological changes in
the cancer genome.
Cancer-specific abnormal expression
changes of genes that have wild-type
DNA sequences are attributable to at
least two mechanisms: gains and losses
in DNA methylation as well as switches
in histone modifications (Baylin and
Jones, 2011). The most highly explored
epigenetic change in cancer is abnormal
DNA methylation in promoter CpG-
islands, it is attendant gene silencing(Baylin and Jones, 2011). These methyla-
tion changes involve the participation
of inactivating histone modifications,
silencing protein complexes, and nucleo-
some occupancy surrounding gene tran-
scription start sites (TSS) (Jones, 2012).
As introduced above, such epigenetic
changes can concordantly occur in
adjacent genes spanning large regions
involving inactive histone modifications
and DNA-methylation in a process called
long-range epigenetic silencing (LRES)
(Coolen et al., 2010) (Figure 1A).
In the context of epigenetic gene
silencing, there are new revelations re-
garding CpG-island hypermethylation,
including LRES, and these are by no
means restricted to or even best under-
stood from focusing solely on abnormal
scenarios like cancer. Deep sequencing
efforts for genome-wide DNA methylation
and chromatin mapping have revealed
broad domains of dense DNA methyla-
tion harboring developmental genes
in embryonic stem cells (ESCs), which
mosaically lose their DNA-methylation
in normal adult cells to form ‘‘partially
methylated domains’’ or PMDs (Fig-
ure 1B). Importantly, these also seem to
be regions where reestablishment of
ESC-like CpG methylation patterns is
incomplete during cellular reprogramming
and cancer-like abnormalities can evolve
(Lister et al., 2011). Moreover, during
tumorigenesis, very significant epigenetic
changes are targeted to these regions.
For example, in colon cancer, PMDs are
shown to lose even more DNA methyla-
tion (20%–60% methylated-CpGs) than
normal colon cells (Berman et al., 2012).
Perhaps most surprisingly, significantly
large numbers of the genes with cancer-
specific promoter CpG-island hyperme-Cancer Cellthylation appear as focal changes within
the PMDs, including LRES-genes.
The widespread and focal shifts in
chromatin and DNA methylation in PMDs
suggest that in cancers there is a loss
of boundaries that regulate chromatin
domains. Excitingly, the field is moving
forward in identifying some of the molec-
ular underpinnings of PMDs and their
alterations in cancer. This understanding
is pivotal to the entire concept of
how epigenomes are organized. First,
although there is global CpG-methylation
loss within these PMDs, there is a
concomitant increase in the inactive
histone modification H3K9me2 observed
as an overlap of the PMDswith large orga-
nized chromatin-lysine-(K)-modifications
(LOCKs) (Hansen et al., 2011). In general,
genes within these PMDs and LOCKs
have low expression. Second, PMDs in
normal cells largely encompass late-
replicating lamin-associated domains in
the nuclear periphery (Berman et al.,
2012). These attributes of PMDs have
important functional ramifications. In
normal settings, DNAmethylation mainte-
nance is less efficient at late-replicating
heterochromatic DNA in the PMDs, and
this may underlie progressive loss of
DNA methylation in these regions during
normal differentiation (Hansen et al.,
2010). This replication-timing relationship
may be accentuated in cancers, possibly
leading to further losses of DNA methyla-
tion in PMDs. Intriguingly, PMDs harbor
significant numbers of developmental
genes, which in ESCs are silenced by
polycomb protein complex (PcG) occu-
pancy, but not with DNA methylation in
the promoter CpG-islands. Often, this
promoter chromatin is in a context where
PcG and the active histone modification,23, January 14, 2013 ª2013 Elsevier Inc. 1
Figure 1. Patterns of Long-Range Epigenetic Control Regions in
Normal and Cancer Cells
(A) Long-range epigenetic activation (LREA) domains and long-range epige-
netic silenced (LRES) domains harbor gains in CpG-island methylation. The
CpG-island methylation gains, more usually associated with abnormal gene
silencing, may, in LREAs, result in gene activation if associated with the use
of alternate TSS, inhibition of repressor binding factors, or association with
activating histone modifications. LRES domains harbor inactivating histone
modifications along with promoter CpG-methylation at gene TSS.
(B) Shows the association of the multiple long-range chromatin domains with
epigenomic alterations in cancers. Cancer-specific promoter CpG-island
methylation and LRES genes often occur within PMDs, which are also associ-
ated with other key epigenetic domains like the lamin associated domains
(LADs) and large organized chromatin-lysine-(K) modifications (LOCKs).
LREAs may constitute an additional type of abnormality in cancer.
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‘‘bivalent’’ chromatin, which
holds genes in a poised/low
expression state until activa-
tion or repression during
lineage commitment (Baylin
and Jones, 2011). Studies
from our lab suggest that
about 70% of the promoter
CpG-island hypermethylated
genes in various cancers are
the above PcG-related genes
(Easwaran et al., 2012). These
relationships suggest that
late-replicating PMD regions
are vulnerable to abnormal
silencing with the accrual of
promoter DNA-methylation
of developmental genes in
cancer, which cumulatively
could help maintain sub-
groups of cells with abnormal
self-renewal and/or blocks in
differentiation capacity.
So where do the LREA
domains fit in this concept
of large epigenomic domains
in cancer cells? As stated
earlier, multiple genes in
LREA are abnormally upre-
gulated in prostate cancer
cells compared to normal
prostate epithelial cells orESCs. Not surprisingly then, as opposing
phenomena, LRES and LREA generally
show opposing promoter chromatin
modifications: the former harboring
inactive histone modifications whereas
the latter active histone modifications
(Figure 1A). Intriguingly, however, the
LREA domains have the same frequency
of focal CpG island hypermethylation
gain as in the rest of the cancer genome.
Moreover, even though the authors
observe that LREAs are separated from
PMDs, the genes involved with CpG
island hypermethylation are, as for
PMDs, often those with a history of
PcG-regulation in development (Bert
et al., 2013). This juxtaposition of pro-
moter CpG island hypermethylation with
upregulated genes would seem to con-
tradict its usual association with gene
silencing. One explanation offered by
Bert et al. (2013) is that gene activa-
tion may occur via use of alternate
TSS. For other genes, activation might
involve methylation-mediated inhibition
of repressor binding to promoter regula-2 Cancer Cell 23, January 14, 2013 ª2013 Eltory elements. These proposals merit
further investigation.
An important take-home message from
the aforementioned observations is that
focal promoter CpG island hypermethy-
lation within broad regions of losses of
DNA methylation is a key epigenetic
abnormality in cancer. The study by Bert
et al. (2013) adds to this and raises
additional questions about these domain
changes. The focal promoter DNA hyper-
methylation, while mostly associated
with gene silencing, can, in a context-
dependent manner, be involved in the
activation of a minority of genes as in
the LREA domains. Further studies in
multiple cancer types are required to
define the LREA domains, their differ-
ences from the PMDs, and importantly,
which genes or groups of genes in these
regions are important to tumorigenesis.
For the last question, we need to deter-
mine how often epigenetic abnormalities
in cancer involve genes residing within
long-range chromatin abnormalities. The
precise molecular alterations underlyingsevier Inc.long-range boundary shifts
and altered gene regula-
tion are being revealed, but
much more remains to be
clarified. The role of nuclear
structure and chromatin con-
figurations in this phenom-
enon remains to be eluci-
dated. Further, unbiased
determination of DNA methyl-
ation, chromatin modification
patterns, and nucleosome
localization using next-gener-
ation sequencing across
these domains will help
understand the molecular
basis of these long-range
chromosome changes. One
fascinating question is how
cancer mutations in chro-
matin-regulating genes relate
to these various domains.
Are these long-range regions
and corresponding gene ex-
pression changes a common
downstream readout for
many of these genetic
changes? If so, will thera-
peutic targeting of epigenetic
modifiers provide unified
approaches for treating
patients according to chro-
matin-related gene mutationpatterns in their tumors? An exciting
period of research surely is upon us for
learning more about the biology and
translational ramifications of LRES,
LREA, and PMDs in cancers.ACKNOWLEDGMENTS
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Smoothened inhibitors have emerged as successful treatment alternatives for Hedgehog pathway-
dependent tumors, but they are linked with the appearance of drug resistance. In this issue of Cancer Cell,
Kim and colleagues overcome such resistance by combining approved drugs itraconazole and arsenic
trioxide, thus opening a path toward new treatment options.Inappropriate reactivation of key devel-
opmental signaling pathways in cancer
is a common theme, with Hedgehog
(Hh), Wnt, and Notch pathways being
prime examples. Consequently, focused
efforts to develop inhibitors of these path-
ways are an important part of the broader
drive toward targeted therapy for cancer.
Aberrant activation of Hh signaling, most
often caused by mutational inactivation
of the Hh receptor Patched 1 (PTCH1),
is a feature of basal cell carcinoma of
the skin (BCC) and a subgroup of medul-
loblastomas (MBs). The importance of the
Hh pathway in controlling growth and
differentiation in tissue stem and progen-
itor cells is consistent with the pathway’s
role as a driver in these tumor types.
Unfortunately, as with most cancer drug
treatments, a major limitation of agents
that block Hh signaling is the presence
of preexisting or acquired drug resis-
tance, which prevent cure.
Presently, all drugs in advanced
stages of development for the treatment
of Hh pathway-dependent tumors target
Smoothened (Smo), a seven transmem-
brane G protein coupled receptor. Smo
is present at the cell membrane and is
required for ligand-dependent activationof the Hh pathway. One Smo inhibitor, vis-
modegib (GDC-0449), is FDA-approved
for the treatment of locally advanced
and metastatic BCC. Another four Smo
inhibitors have progressed into phase II
clinical trials (NVP-LDE225, IPI-926, XL-
139, and LY2940680). Two adult patients
with end-stage MB showed excellent
responses to vismodegib treatment with
tumor shrinkage lasting up to five months;
however, tumor relapse eventually
occurred in both cases (Asklund et al.,
2012; Rudin et al., 2009). More recently,
reports of vismodegib resistance in BCC
patients have also appeared (Atwood
et al., 2012). Smo inhibitor resistance
may develop by several different mecha-
nisms, including de novo mutations in
SMO, amplification of Gli2 and Ccnd1
(the cyclin D1 gene), PI3K-mTORpathway
activation, and induction of drug efflux by
P-glycoprotein (PGP) (Atwood et al.,
2012; Buonamici et al., 2010; Yauch
et al., 2009) (Figure 1). Hence, with the
anticipated increase in the clinical use of
Smo inhibitors, an increase in the preva-
lence of Smo inhibitor resistance is
expected.
In this issue of Cancer Cell, Kim et al.
(2013) present a highly relevant studyshowing that two FDA-approved drugs,
itraconazole and arsenic trioxide (ATO),
inhibit Hh pathway activation and tumor
growth associated with acquired resis-
tance to Smo antagonists. The group
had shown earlier that itraconazole, an
anti-fungal agent, inhibits Hh signaling at
the level of Smo by a mechanism different
from cyclopamine and prevents the ciliary
Smo accumulation normally resulting
from Hh activation. Functioning at a
different part of the Hh pathway, ATO
antagonizes Gli effectors downstream of
Smo by inhibiting GLI1 transcriptional
activity and blocking Hh-induced Gli2
ciliary accumulation (Beauchamp et al.,
2011; Kim et al., 2010).
Since itraconazole and ATO inhibit the
Hh pathway at distinct levels, Kim et al.
(2013) tested the two compounds alone
and in combination to assess efficacy in
tumors with acquired resistance to Smo
inhibitor. First, they showed that itracona-
zole alone blocked proliferation to similar
degrees in parental (SmoWT) and vismo-
degib-resistant (SmoD447G) MB cells
growing in spheroids derived from
Ptch+/;p53/ mice. However, a Gli-
dependent reporter-based system re-
vealed that itraconazole only partially23, January 14, 2013 ª2013 Elsevier Inc. 3
